ConductScience.org, home

Paper4609488

Negamycin inhibits termination of protein synthesis directed by phage f2 RNA in vitro.

Uehara Y and 2 others. Biochim Biophys Acta, 1974. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Negamycin inhibits termination of protein synthesis directed by phage f2 RNA in vitro. Papers, record 4609488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4609488

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Negamycin inhibits termination of protein synthesis directed by phage f2 RNA in vitro.
PubMed
Journal
Biochim Biophys Acta
PubMed
Year
1974
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
0.54
iCite
Revised in PubMed
2019-06-09
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Uehara YY
2Hori MM
3Umezawa HH

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amino Acids, DiaminoMajor topic
Anti-Bacterial AgentsMajor topic
Bacterial ProteinsMajor topic
ColiphagesMajor topic
Escherichia coliMajor topic
Peptide Chain Termination, TranslationalMajor topic
Protein BiosynthesisMajor topic
RNA, ViralMajor topic
Viral ProteinsMajor topic
Carbon Radioisotopes
Centrifugation, Density Gradient
Electrophoresis, Polyacrylamide Gel
Hydrazines
Isotope Labeling
RNA Viruses
RNA, Bacterial
Ribosomes
Streptomycin
Time Factors
Valine

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
33468467The Antibiotic Negamycin Crosses the Bacterial Cytoplasmic Membrane by Multiple Routes.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33468467PubMed
26288696Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens.ACS Med Chem Lett2015https://conductscience.org/library/papers/26288696PubMed
25368144Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosome.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/25368144PubMed
25306922Negamycin interferes with decoding and translocation by simultaneous interaction with rRNA and tRNA.Mol Cell2014https://conductscience.org/library/papers/25306922PubMed
24900441Negamycin analogue with readthrough-promoting activity as a potential drug candidate for duchenne muscular dystrophy.ACS Med Chem Lett2012https://conductscience.org/library/papers/24900441PubMed
6901544Ribosomal function and its inhibition by antibiotics in prokaryotes.Naturwissenschaften1980https://conductscience.org/library/papers/6901544PubMed
1783523Antitumor activity and mechanism of action of the marine compound girodazole.Invest New Drugs1991https://conductscience.org/library/papers/1783523PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4609488

GET https://conductscience.org/api/papers/v1/4609488/authors